https://scholars.lib.ntu.edu.tw/handle/123456789/558561
標題: | Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids | 作者: | Huang T.-M. Kuo K.-C. Wang Y.-H. Wang C.-Y. Lai C.-C. HAO-CHIEN WANG Chen L. CHONG-JEN YU |
公開日期: | 2020 | 出版社: | BioMed Central Ltd | 卷: | 20 | 期: | 1 | 起(迄)頁: | 706 | 來源出版物: | BMC Infectious Diseases | 摘要: | Objectives: To investigate the incidence of active tuberculosis (TB) among COPD patients using fluticasone/salmeterol or budesonide/formoterol, and to identify any differences between these two groups of patients. Methods: The study enrolled COPD patients from Taiwan NHIRD who received treatment with fluticasone/salmeterol or budesonide/formoterol for > 90 days between 2004 and 2011. The incidence of active TB was the primary outcome. Results: Among the intention-to-treat population prior to matching, the incidence rates of active TB were 0.94 and 0.61% in the fluticasone/salmeterol and budesonide/formoterol groups, respectively. After matching, the fluticasone/salmeterol group had significantly higher rates of active TB (adjusted HR, 1.41, 95% CI, 1.17-1.70) compared with the budesonide/formoterol group. The significant difference between these two groups remained after a competing risk analysis (HR, 1.45, 95% CI, 1.21-1.74). Following propensity score matching, the fluticasone/salmeterol group had significantly higher rates of active TB compared with the budesonide/formoterol group (adjusted HR, 1.45, 95% CI, 1.14-1.85). A similar trend was observed after a competing risk analysis (HR, 1.44, 95% CI, 1.19-1.75). A higher risk of active TB was observed in the fluticasone/salmeterol group compared with the budesonide/formoterol group across all subgroups, but some differences did not reach statistical significance. Conclusion: Fluticasone/salmeterol carried a higher risk of active TB compared with budesonide/formoterol among COPD patients. ? 2020 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091808299&doi=10.1186%2fs12879-020-05440-6&partnerID=40&md5=88e5c4a0d97d6583952ab5cdb02f9091 https://scholars.lib.ntu.edu.tw/handle/123456789/558561 |
ISSN: | 1471-2334 | DOI: | 10.1186/s12879-020-05440-6 | SDG/關鍵字: | budesonide plus formoterol; fluticasone propionate plus salmeterol; beta 2 adrenergic receptor stimulating agent; budesonide plus formoterol; corticosteroid; fluticasone propionate plus salmeterol; adult; aged; Article; chronic obstructive lung disease; cohort analysis; controlled study; female; human; incidence; infection risk; intention to treat analysis; major clinical study; male; outcome assessment; propensity score; risk assessment; statistical significance; Taiwan; trend study; tuberculosis; chronic obstructive lung disease; follow up; inhalational drug administration; middle aged; Mycobacterium tuberculosis; risk factor; tuberculosis; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Budesonide, Formoterol Fumarate Drug Combination; Female; Fluticasone-Salmeterol Drug Combination; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Mycobacterium tuberculosis; Propensity Score; Pulmonary Disease, Chronic Obstructive; Risk Factors; Taiwan; Tuberculosis |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。